期刊文献+

益肾壮骨汤治疗骨质疏松症临床研究 被引量:13

Clinical Study on Kidney-Benefiting and Bone-Strengthening Decoction for Treating Osteoporosis
下载PDF
导出
摘要 目的:观察益肾壮骨汤联合仙灵骨葆胶囊治疗骨质疏松症的临床疗效。方法:将2012年3月—2014年10月本院诊治的骨质疏松症患者116例,随机分为对照组和观察组各58例。对照组患者给予仙灵骨葆胶囊治疗,观察组患者在对照组基础上给予益肾壮骨汤内服治疗,1剂·d-1,连续治疗6个月。观察两组患者临床疗效。结果:对照组有效率为75.9%,明显低于观察组有效率91.3%,差异有统计学意义(P<0.05);患者经治疗后疼痛症状明显缓解,VAS评分随着治疗时间的延长而降低,以观察组的降低幅度更为明显,差异有统计学意义(P<0.05);患者经治疗后L2-L4椎骨及股骨颈的骨密度均较治疗前升高,观察组的变化幅度明显高于对照组,差异有统计学意义(P<0.05);两组患者经治疗后骨代谢生化指标水平改善明显,β-I型胶原羧基端肽(β-CTX)、碱性磷酸酶水平均较治疗前降低,而血清钙、骨钙素水平则较治疗前升高,以观察组的改善程度更突出,差异有统计学意义(P<0.05)。结论:益肾壮骨汤联合仙灵骨葆胶囊能有效缓解骨质疏松症患者的疼痛症状,提高骨密度,促进骨形成,疗效显著。 Objective: To observe the clinical effect of Kidney-Benefiting and Bone-Strengthening Decoction combined with Xianling Gubao Capsules on osteoporosis. Methods: 116 cases with osteoporosis received by this hospital from March,2012 to October,2014 were randomized into control group and observation group,with 58 cases in each group. Control group were given Xianling Gubao Capsules and observation group were additionally given Kidney-Benefiting and Bone-Strengthening Decoction for oral administration,with one dosage every day. After 6 months of treatment,the clinical effect of both groups were observed. Results: The effective rate in control group( 75. 9%) was obviously lower than that in observation group( 91. 3%); the difference had statistical significance( P 〈0. 05). The pain of the patients got obviously improved after the treatment. The VAS declined with the process of the treatment and the decline in observation group was much more obvious,with statistical significance( P 〈0. 05). The bone mineral density of L2-L4 vertebra and collum femoris increased after the treatment and the change in observation group was bigger than that in control group,with statistical significance( P 〈0. 05). The levels of biochemical indexes of bone metabolism of both groups improve markedly; the levels of β-CTX and alkaline phosphatase declined while the levels of serum calcium and osteocalcin increased after the treatment; the improvement of observation group was much much remarkable and the difference had statistical significance( P 〈0. 05). Conclusion: Kidney-Benefiting and Bone-Strengthening Decoction combined with Xianling Gubao Capsules can relieve the pain of patients with osteoporosis,increase the bone mineral density and promote bone formation with remarkable efficacy.
作者 廖远建
出处 《河南中医》 2015年第6期1325-1327,共3页 Henan Traditional Chinese Medicine
关键词 骨质疏松症 益肾壮骨汤 仙灵骨葆胶囊 osteoporosis Kidney-Benefiting and Bone-Strengthening Decoction Xianling Gubao Capsules
  • 相关文献

参考文献9

二级参考文献28

  • 1李平生.老年人骨质疏松症[J].人民军医,2004,47(7):419-421. 被引量:28
  • 2刘忠厚,杨定焯,朱汉民,王洪复,张柳,唐海,赵燕玲.中国人原发性骨质疏松症诊断标准(试行)[J].中国骨质疏松杂志,1999,5(1):1-3. 被引量:244
  • 3原发性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):455-457. 被引量:65
  • 4黄宏兴,柴生颋,黄红,陈希,陈彦东.骨质疏松症中医证型的聚类分析[J].广州中医药大学学报,2007,24(3):180-183. 被引量:56
  • 5赵定麟.现代脊柱外科学[M].上海:世界图书出版公司,2006.1167.
  • 6Burge R, Dawson-Hughes B, Solomon DH, et al. incidence and e- conomic burden of osteoporosis-related fractures in the United States ,2005-2025 [ J]. J Bone Miner Res ,2007,22:465 - 475.
  • 7Brown JP,Fortier M,Frame H, et al. Canadian Consensus Confer- ence on osteoporosis, 2006 update. Osteoporosis Guidelines Com- mittee[ J]. J Obstet Gynaecol Can, 2006,28 ( 2 Suppl 1 ) : S95 - 112.
  • 8Riggs BL,Melton LJ, Robb RA,et al. A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites [ J ]. J Bone Miner Res, 2004,19 (12) :1945 - 1954.
  • 9Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis[ J]. Endocrinol Metab Clin N Am, 2005,34 (4): 1015 - 1030.
  • 10Sun L, Peng YZ, Sharrow AC, et at. FSH directly regulates bone mass[ J]. Cell ,2006,125 ( 2 ) :247 - 260.

共引文献1340

同被引文献139

  • 1程晓光(译),刘忠厚(校).国际临床骨密度学会共识文件(2005年版)[J].中国骨质疏松杂志,2006,12(2):205-209. 被引量:68
  • 2王清任,周计春.医林改错[M].北京:人民军医出版社,2007:19-20,71-73.
  • 3霍志刚,郑清莲,李信民,刘俊田,刘永惠.胎肾细胞悬液对去卵巢骨质疏松大鼠骨生物力学性能的影响[J].中国骨质疏松杂志,2007,13(12):854-857. 被引量:9
  • 4Gorai I.Bone and Calcium Research Update 2015.Therapy of osteoporosis-Now and future consideration of long-term therapy[J].Clinical Calcium,2015,25(1):105-113.
  • 5Svedbom A,Alvares L,Cooper C,et al.Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture:a UK cost effectiveness analysis[J].Osteoporos International,2013,24(1):355-367.
  • 6Walter J,Haciyakupoglu E,Waschke A,et al.Cement leakage as a possible complication of balloon kyphoplasty--is there a difference between osteoporotic compression fractures and incomplete burst fractures[J].Acta Neurochir(Wien),2012,154(2):313-319.
  • 7Svejme O,Ahlborg H G,Nilsson J A,et al.Early menopause and risk of osteoporosis,fracture and mortality:a 34-year prospective observational study in 390 women[J].Bjog An International Journal of Obstetrics&Gynaecology,2012,119(7):810-816.
  • 8Molina G S,Campero A,Feito R,et al.Kyphoplasty in the treatment of osteoporotic Vertebral Compression Fractures(OVCFS):procedure description and analysis of the outcomes in128 patients[J].Acta Neurochir Suppl,2011,108(108):163-170.
  • 9Li Y A,Lin C L,Chang M C,et al.Subsequent vertebral fracture after vertebroplasty:incidence and analysis of risk factors[J].Spine(Phila Pa 1976),2011,37(3):179-183.
  • 10Nagaraja S,Awada H K,Dreher M L,et al.Vertebroplasty increases compression of adjacent IVDs and vertebrae in osteoporotic spines[J].Spine J,2013,13(12):1872-1880.

引证文献13

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部